Breast Cancer, Cancer Research, JAMA, Weight Research / 13.05.2026

MedicalResearch.com Interview with: [caption id="attachment_73639" align="alignleft" width="125"]Bernard F. Fuemmeler, PhD, MPHProfessor and Gordon D. Ginder, MD Chair in Cancer Research Associate Director of Population Science, Massey Comprehensive Cancer Center Director of Research, Family Medicine and Population Health Dr. Fuemmeler[/caption] Bernard F. Fuemmeler, PhD, MPH Professor and Gordon D. Ginder, MD Chair in Cancer Research Associate Director of Population Science, Massey Comprehensive Cancer Center Director of Research, Family Medicine and Population Health [caption id="attachment_73640" align="alignleft" width="125"]Kristina L. Tatum, PsyD, MSInstructor Department of Social and Behavioral Sciences School of Public Health Dr. Tatum[/caption] Kristina L. Tatum, PsyD, MS Instructor Department of Social and Behavioral Sciences School of Public Health A large population-based analysis of more than 841,000 breast cancer patients across the United States examines whether GLP-1 receptor agonist use is associated with improved survival and lower recurrence risk — with findings that researchers describe as very promising.
MedicalResearch.com: What is the background for this study? What are the main findings? Response: Glucagon-like peptide-1 receptor agonists, or GLP-1RAs, have been used since 2005 and as the GLP1RAs treatments and delivery methods have improved, their use has markedly increased. Now it is estimated that nearly 1 in 8 US adults report ever using a GLP-1RA, which includes many people who are using them to treat obesity, diabetes, heart disease, and sleep apnea. There has been some preclinical data from mouse models to suggest that maybe GLP1RAs have an anticancer effect reducing the effects of obesity on tumor growth or progression. We were interested to understand to what extent GLP1RA use among cancer patients might be associated with cancer outcomes, like length of survival after cancer treatment or the chance of recurrence. In our large population-based study using an aggregate of de-identified electronic health record data from more than 841,000 patients with breast cancer across the US, we found that GLP-1 RAs use was associated with significantly improved survival and lower recurrence risk among patients with obesity or type 2 diabetes. Among patients with obesity, GLP-1 RAs use was associated with approximately 65% lower risk of death and a 56% lower risk of recurrence over 10 years compared with nonuse. We also observed substantially improved outcomes among patients with type 2 diabetes compared with insulin or metformin.
Weight Research / 11.05.2026

weight-loss-with-new-oral-medications.png

Key Takeaways

     
  • GLP-1 medications have revolutionized weight loss treatment, offering both injectable and oral options.
  • Recent FDA approvals have expanded access to these medications, with new oral formulations now available.
  • While effective, GLP-1 medications can have side effects, emphasizing the need for medical supervision.
  • Incorporating dietary fiber can help mitigate some gastrointestinal side effects associated with GLP-1 medications.
 

Table of Contents

  1. Introduction
  2. Understanding GLP-1 Medications
  3. Recent FDA Approvals
  4. Potential Side Effects
  5. Dietary Considerations
  6. Importance of Medical Supervision
  7. Conclusion
 

Introduction

In recent years, the field of weight management has experienced significant changes, thanks to a class of drugs called GLP-1 receptor agonists. These medications, which started as treatments for type 2 diabetes, have demonstrated remarkable success in supporting weight loss. Their widespread acceptance and endorsements by healthcare providers stem from their ability to help users not only lose weight but also maintain healthier lifestyles over the long term. Individuals seeking up-to-date and reputable information on options like Semaglutide for Weight Loss can explore how these solutions have changed the landscape of obesity treatment. In recent years, the field of weight management has experienced significant changes, thanks to a class of drugs called GLP-1 receptor agonists. These medications, which started as treatments for type 2 diabetes, have demonstrated remarkable success in supporting weight loss. Their widespread acceptance and endorsements by healthcare providers stem from their ability to help users not only lose weight but also maintain healthier lifestyles over the long term. GLP-1 medications are reshaping how both doctors and patients approach chronic weight issues. Unlike older interventions, these medications address appetite regulation at a hormonal level. With the introduction of oral alternatives, more people can now benefit from these scientifically backed therapies.